Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same author

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Haematologica·2026
Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026
Same author

Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in Australia.

International journal of cancer·2026
Same author

Diet and risk of multiple myeloma: findings from a case-control study.

The British journal of nutrition·2026
Same author

Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? - the PRO.

Haematologica·2026

Related Experiment Video

Updated: Apr 29, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Brian T Grainger1, Joshua Casan2,3, Chathuri Abeyakoon1,4

  • 1Epworth Centre for Immunotherapies and Snowdome Laboratories, Epworth HealthCare, Richmond, VIC, Australia.

Expert Opinion on Pharmacotherapy
|April 28, 2026
PubMed
Summary

Innovative treatments are needed for relapsed or refractory Peripheral T-cell Lymphomas (PTCLs). Personalized strategies using immunotherapies and targeted agents show promise for improving outcomes in these aggressive hematologic malignancies.

Keywords:
CAR T-cell therapyLymphomaimmunotherapymonoclonal antibodiesnovel agents

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Related Experiment Videos

Last Updated: Apr 29, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

13.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Peripheral T-cell lymphomas (PTCLs) are aggressive cancers of mature T- and NK cells.
  • Current frontline chemotherapy (e.g., CHOP) has limited efficacy for relapsed or refractory PTCL.
  • Allogeneic stem cell transplantation offers curative potential but faces barriers.

Purpose of the Study:

  • To review innovative management strategies for relapsed or refractory PTCL.
  • To highlight the need for personalized treatment approaches.
  • To guide clinicians in optimizing care for PTCL patients.

Main Methods:

  • Comprehensive literature search of PubMed, MEDLINE, and EMBASE up to 2026.
  • Review of conventional and emerging treatment modalities.
  • Analysis of recent advances in PTCL management.

Main Results:

  • Brentuximab vedotin improves survival in specific PTCL subtypes like ALCL.
  • Most patients with PTCL experience relapse or refractory disease after initial treatment.
  • Emerging therapies include immunotherapies, epigenetics, and small-molecule inhibitors.

Conclusions:

  • A shift towards personalized medicine is crucial for PTCL management.
  • Tailoring treatments based on disease subtype is essential.
  • Further research into novel agents and strategies is needed to address unmet clinical needs.